论文部分内容阅读
目的:通过检测Smad2与TGF-β1基因在胰腺癌中的表达,初步探讨它们与胰腺癌临床病理的关系。方法:采用免疫组织化学pv-9000法检测50例胰腺癌组织和10例正常胰腺组织中Smad2与TGF-β1的表达情况,并分析其与胰腺癌临床病理的相关性。结果:Smad2与TGF-β1在胰腺癌组织中的表达水平显著高于正常胰腺组织,两组之间存在显著差异(P<0.05)。在胰腺癌组织中,Smad2与TGF-β1的表达在胰腺癌不同分期中存在显著差异(P<0.05)。结论:Smad2与TGF-β1在胰腺癌中高表达,二者联合可作为反映胰腺癌临床分期的生物学指标。
Objective: To detect the expression of Smad2 and TGF-β1 in pancreatic cancer and to explore their relationship with clinicopathology of pancreatic cancer. Methods: Immunohistochemical pv-9000 method was used to detect the expression of Smad2 and TGF-β1 in 50 cases of pancreatic cancer and 10 cases of normal pancreatic tissues. The correlation between the expression of Smad2 and TGF-β1 in pancreatic cancer was analyzed. Results: The expression levels of Smad2 and TGF-β1 in pancreatic cancer tissues were significantly higher than those in normal pancreatic tissues. There was a significant difference between the two groups (P<0.05). In pancreatic cancer tissues, there was a significant difference in the expression of Smad2 and TGF-β1 in different stages of pancreatic cancer (P<0.05). Conclusion: Smad2 and TGF-β1 are highly expressed in pancreatic cancer. The combination of Smad2 and TGF-β1 can be used as a biological indicator reflecting the clinical stage of pancreatic cancer.